<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510155</url>
  </required_header>
  <id_info>
    <org_study_id>NL72118.068.20</org_study_id>
    <nct_id>NCT04510155</nct_id>
  </id_info>
  <brief_title>Liver Glycogen Dynamics</brief_title>
  <acronym>LGD</acronym>
  <official_title>Liver Glycogen Dynamics and Substrate Oxidation in Lean Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of prolonged overnight fasting in the&#xD;
      hepatic glycogen stores&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Actual">May 21, 2021</completion_date>
  <primary_completion_date type="Actual">May 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic glycogen content</measure>
    <time_frame>1 hour</time_frame>
    <description>Measured with 13C-MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substrate oxidation</measure>
    <time_frame>14 hours</time_frame>
    <description>Measured as RQ</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intrahepatic fat content and composition (1H-MRS)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Measured with 1H-MRS</description>
  </other_outcome>
  <other_outcome>
    <measure>De novo lipogenesis (DNL)</measure>
    <time_frame>20 hours</time_frame>
    <description>measured as percentage of palmitate in VLDL-TG originating from DNL</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic fat oxidation</measure>
    <time_frame>5 hours</time_frame>
    <description>measured as plasma BHB levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver volume</measure>
    <time_frame>5 minutes</time_frame>
    <description>Measured with MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Substrate oxidation</measure>
    <time_frame>30 minutes</time_frame>
    <description>measured with indirect calorimetry</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma metabolites related to energy metabolism</measure>
    <time_frame>5 hours</time_frame>
    <description>measured in plasma samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>5 minutes</time_frame>
    <description>fat mass/fat free mass measured with BodPod</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatic Glycogen</condition>
  <arm_group>
    <arm_group_label>Short overnight fast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long overnight fast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Overnight fasting duration</intervention_name>
    <description>Subjects will adhere to overnight fasting protocol for 1 day</description>
    <arm_group_label>Long overnight fast</arm_group_label>
    <arm_group_label>Short overnight fast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants are able to provide signed and dated written informed consent prior to&#xD;
             any study specific procedures&#xD;
&#xD;
          -  Caucasian (people will be excluded when having a ≥50% racial African/Asian background)&#xD;
&#xD;
          -  Participants should have suitable veins for cannulation or repeated venipuncture&#xD;
&#xD;
          -  Women are post-menopausal (defined as at least 1 year post cessation of menses)&#xD;
&#xD;
          -  Men and women aged ≥ 45 and ≤ 75 years at the start of the study&#xD;
&#xD;
          -  Body mass index (BMI) 18.5 - 25 kg/m2&#xD;
&#xD;
          -  Stable dietary habits (no weight loss or gain &gt;3kg in the past 3 months)&#xD;
&#xD;
          -  Sedentary lifestyle (not more than 3 hours of vigorous sports per week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other)&#xD;
&#xD;
          -  Any contraindication for MRI scanning&#xD;
&#xD;
          -  Alcohol consumption of &gt;2 servings per day&#xD;
&#xD;
          -  Regular smoking&#xD;
&#xD;
          -  No use of medication interfering with investigated study parameters (as determined by&#xD;
             responsible physician)&#xD;
&#xD;
          -  Participants who do not want to be informed about unexpected medical findings, or do&#xD;
             not wish that their physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Schrauwen-Hinderling, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University</investigator_affiliation>
    <investigator_full_name>Charlotte Andriessen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

